Linked Life Data

19105712

Source:http://linkedlifedata.com/resource/pubmed/id/19105712

Statements in which the resource exists as a subject.
PredicateObject
rdf:type
lifeskim:mentions
pubmed:issue
1
pubmed:dateCreated
2008-12-24
pubmed:abstractText
After nearly 40 years of treatment of metastatic colorectal cancer with 5-fluorouracil (5-FU) or best supportive care, the treatment of this disease has evolved rapidly in the last decade. Treatment options now include several new cytotoxic and biologic agents. Combination regimens, such as folinic acid, 5-FU plus oxaliplatin (FOLFOX), and folinic acid, 5-FU plus irinotecan (FOLFIRI), have significantly improved clinical efficacy as related to response rates and overall survival. The optimum integration of chemotherapy regimens with biological agents targeting critical signaling pathways, such as, bevacizumab (monoclonal antibody targeting VEGF-A), cetuximab and panitumumab (monoclonal antibodies targeting the EGF receptor) are still under evaluation. With the availability of several treatment options, however, comes the issue of optimal duration of chemotherapy in order to achieve the dual goals of clinical efficacy and quality of life, and the issue of cost-effectiveness of treatment, particularly with the newer targeted therapies. One method of achieving this may be to accommodate planned treatment holidays so patients can recover from the physical and psychological side effects of their chemotherapy as long as clinical efficacy is not compromised. In this review, we discuss the evidence for the use of intermittent chemotherapy in metastatic colorectal cancer.
pubmed:language
eng
pubmed:journal
pubmed:citationSubset
IM
pubmed:chemical
pubmed:status
MEDLINE
pubmed:month
Jan
pubmed:issn
1744-8328
pubmed:author
pubmed:issnType
Electronic
pubmed:volume
9
pubmed:owner
NLM
pubmed:authorsComplete
Y
pubmed:pagination
125-34
pubmed:meshHeading
pubmed:year
2009
pubmed:articleTitle
Intermittent therapy in the palliative treatment of metastatic colorectal cancer.
pubmed:affiliation
Velindre Hospital, Whitchurch, Cardiff, UK. anshu.wadhawan@velindre-tr.wales.nhs.uk
pubmed:publicationType
Journal Article, Review